Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dave Singh

Showing results (371-380 of 505) with videos related to

Pageof 51
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2011
The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokinesJulie E Gibbs, John Blaikley, Stephen Beesley, et al.
Chest|December 4, 2024
The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPDBartolome R Celli, Antonio Anzueto, Dave Singh, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 14, 2022
Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT TrialJ Michael Wells, Gerard J Criner, David M G Halpin, et al.
Pulmonary Therapy|June 23, 2026
Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled TrialsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Respiratory Medicine|October 13, 2019
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocolKlaus F Rabe, Fernando J Martinez, Gary T Ferguson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 5, 2020
Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority StudyJaco Voorham, Simonetta Baldi, Luigi Santoro, et al.
The European Respiratory Journal|October 28, 2024
ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPDR Chad Wade, Fernando J Martinez, Gerard J Criner, et al.
Respiratory Research|July 18, 2020
ADAM15 expression is increased in lung CD8<sup>+</sup> T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstructionXiaoyun Wang, Duo Zhang, Andrew Higham, et al.
Pulmonary Pharmacology & Therapeutics|March 29, 2023
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot studyGilberto DeNucci, Tom Wilkinson, Carlos Sverdloff, et al.
The European Respiratory Journal|September 10, 2021
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPDDave Singh, Jutta Beier, Carol Astbury, et al.
Pageof 51

Showing results (371-380 of 505) with videos related to

Sort By:
Pageof 51
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2011
The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokinesJulie E Gibbs, John Blaikley, Stephen Beesley, et al.
Chest|December 4, 2024
The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPDBartolome R Celli, Antonio Anzueto, Dave Singh, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 14, 2022
Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT TrialJ Michael Wells, Gerard J Criner, David M G Halpin, et al.
Pulmonary Therapy|June 23, 2026
Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled TrialsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Respiratory Medicine|October 13, 2019
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocolKlaus F Rabe, Fernando J Martinez, Gary T Ferguson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 5, 2020
Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority StudyJaco Voorham, Simonetta Baldi, Luigi Santoro, et al.
The European Respiratory Journal|October 28, 2024
ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPDR Chad Wade, Fernando J Martinez, Gerard J Criner, et al.
Respiratory Research|July 18, 2020
ADAM15 expression is increased in lung CD8<sup>+</sup> T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstructionXiaoyun Wang, Duo Zhang, Andrew Higham, et al.
Pulmonary Pharmacology & Therapeutics|March 29, 2023
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot studyGilberto DeNucci, Tom Wilkinson, Carlos Sverdloff, et al.
The European Respiratory Journal|September 10, 2021
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPDDave Singh, Jutta Beier, Carol Astbury, et al.
Pageof 51